SOPHiA GENETICS SA (SOPH) Stock Price, Financials & Summary

Price chart

Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3

Key dataNov 3, 2026

Open$6.50

From 52W high−22.53%

Volume2.31M

Market cap$588.23M

P/E (TTM)—

P/S (TTM)6.8x

Div yield—

Key dataNov 3, 2026

Open

$6.50

From 52W high

−22.53%

Volume

2.31M

Market cap

$588.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−8.5x

P/E (TTM)

—

RSI (14)

43.9

MomentumView details →

1D Return

−2.81%

YTD Return

+51.82%

SummaryUpdated Sep 1, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH) is a Swiss healthcare technology company founded in 2011 and headquartered in Saint-Sulpice, Switzerland. The company went public in July 2021, positioning itself as a leader in data-driven medicine through artificial intelligence and cloud computing. SOPHiA GENETICS has built a global platform that serves hospitals, laboratories, and biopharmaceutical companies across more than 70 countries, with nearly 800 healthcare institutions using its technology to analyze genomic data for precision medicine applications.

Ask drillr about SOPHiA GENETICS SA →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−8.5x

EV/Sales

6.3x

P/S (TTM)

6.8x

P/B (TTM)

7.1x

ProfitabilityView details →

Gross Margin

66.63%

Net Margin

−93.86%

EBITDA Margin

−74.02%

ROE (TTM)

−97.31%

ROA (TTM)

−40.77%

Asset Turnover

0.48x

GrowthView details →

Revenue YoY

+23.65%

EPS YoY

−4.55%

FCF YoY

−2.65%

Revenue CAGR 3Y

+17.56%

EPS CAGR 3Y

−23.16%

EBITDA YoY

−18.67%

MomentumView details →

1D Return

−2.81%

YTD Return

+51.82%

1Y Return

+51.50%

RSI (14)

43.9

vs 50D SMA

−9.28%

vs 200D SMA

+18.80%

Capital & dividendView details →

Debt/Equity

0.74x

Current Ratio

2.69x

Quick Ratio

2.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.24

EPS Surprise

−21.21%

Beats (12Q)

4/12

Next Q EPS Est

−$0.17

Avg Surprise (4Q)

−19.45%

Rev Surprise

0.95%

Financials snapshotView financials →

Revenue (TTM)

90.97M

Net Income (TTM)

−81.13M

Op. CF (TTM)

−42.28M

Next earningsMar 2, 2027 →

Latest newsMore news →

SOPHiA GENETICS SA said it expects full-year 2026 revenue at the upper end of its previously issued $94 million to $96 million guidance range.1d ago

SOPHiA GENETICS SA reported third-quarter 2026 revenue of $24.3 million, gross margin of 65.7% reported and 72.8% adjusted, net loss of $20.3 million, and adjusted EBITDA loss of $6.1 million.1d ago

Similar companies

HealthyWay Inc.02587.HK National Research CorporationNRC QingSong Health Corp02661.HK Evolent Health, Inc.EVH Phreesia, Inc.PHR MedSci Healthcare Holdings Limited02415.HK Find similar companies →

Latest newsMore news →

SOPHiA GENETICS SA said it expects full-year 2026 revenue at the upper end of its previously issued $94 million to $96 million guidance range.1d ago SOPHiA GENETICS SA reported third-quarter 2026 revenue of $24.3 million, gross margin of 65.7% reported and 72.8% adjusted, net loss of $20.3 million, and adjusted EBITDA loss of $6.1 million.1d ago SOPHiA GENETICS SA announced that it will release its third-quarter 2026 financial results before U.S. markets open on November 3, 2026, and hold a conference call at 8:00 a.m. that day.15d ago